US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

CRSP

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics AG

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CRSP

1 2 3 4 5 6 7 8 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
09/05/2024	07:30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference	NASDAQ:CRSP	CRISPR Therapeutics AG
08/05/2024	15:20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRSP	CRISPR Therapeutics AG
08/05/2024	15:00	GlobeNewswire Inc.	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:CRSP	CRISPR Therapeutics AG
08/05/2024	06:00	GlobeNewswire Inc.	CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach	NASDAQ:CRSP	CRISPR Therapeutics AG
22/04/2024	15:30	GlobeNewswire Inc.	CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	NASDAQ:CRSP	CRISPR Therapeutics AG
03/04/2024	07:00	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	NASDAQ:CRSP	CRISPR Therapeutics AG
01/04/2024	07:00	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	NASDAQ:CRSP	CRISPR Therapeutics AG
13/03/2024	07:30	GlobeNewswire Inc.	CRISPR Therapeutics Proposes New Appointment to the Board of Directors	NASDAQ:CRSP	CRISPR Therapeutics AG
21/02/2024	16:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
21/02/2024	06:50	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CRSP	CRISPR Therapeutics AG
21/02/2024	06:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRSP	CRISPR Therapeutics AG
21/02/2024	06:30	GlobeNewswire Inc.	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CRSP	CRISPR Therapeutics AG
15/02/2024	15:30	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
15/02/2024	07:30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	NASDAQ:CRSP	CRISPR Therapeutics AG
13/02/2024	07:44	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CRSP	CRISPR Therapeutics AG
13/02/2024	07:30	GlobeNewswire Inc.	CRISPR Therapeutics Announces $280 Million Registered Direct Offering	NASDAQ:CRSP	CRISPR Therapeutics AG
13/02/2024	01:30	GlobeNewswire Inc.	European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)	NASDAQ:CRSP	CRISPR Therapeutics AG
29/01/2024	15:00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CRSP	CRISPR Therapeutics AG
16/01/2024	15:01	GlobeNewswire Inc.	CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia	NASDAQ:CRSP	CRISPR Therapeutics AG
08/01/2024	06:00	GlobeNewswire Inc.	CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook	NASDAQ:CRSP	CRISPR Therapeutics AG
03/01/2024	07:30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:CRSP	CRISPR Therapeutics AG
08/12/2023	15:11	Dow Jones News	Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment	NASDAQ:CRSP	CRISPR Therapeutics AG
08/12/2023	11:52	Business Wire	Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease	NASDAQ:CRSP	CRISPR Therapeutics AG
08/12/2023	10:46	Dow Jones News	CRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in Sickle-Cell Disease	NASDAQ:CRSP	CRISPR Therapeutics AG
04/12/2023	15:15	GlobeNewswire Inc.	CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease	NASDAQ:CRSP	CRISPR Therapeutics AG
16/11/2023	00:45	Business Wire	Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	NASDAQ:CRSP	CRISPR Therapeutics AG
06/11/2023	15:15	GlobeNewswire Inc.	CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:CRSP	CRISPR Therapeutics AG
06/11/2023	04:01	GlobeNewswire Inc.	CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023	NASDAQ:CRSP	CRISPR Therapeutics AG
01/11/2023	05:29	Dow Jones News	Crispr Therapeutics Shares Rally Premarket After Favorable FDA Panel Meeting	NASDAQ:CRSP	CRISPR Therapeutics AG
31/10/2023	16:53	GlobeNewswire Inc.	CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease	NASDAQ:CRSP	CRISPR Therapeutics AG

Showing the most relevant articles for your search:NASDAQ:CRSP

1 2 3 4 5 6 7 8 Próxima >

Doubleline Commercial Re...

Roboserver Systems (CE)

RSE Archive (GM)

Melodiol Global Health (GM)

Koninklijke Bam Groep NV (PK)

Lithium Chile (PK)

Jpmorgan Chase Financial...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones